Analytic insights into the population level impact of imperfect prophylactic HIV vaccines

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue 4, 2007, Pages 454-467

  Abu Raddad, Laith J ^a,b   Boily, Marie Claude ^c   Self, Steve ^a   Longini Jr , Ira M ^b,d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

HIV; Infectious disease; Mathematical model; Vaccine efficacy; Vaccines

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; DRUG EFFICACY; HEALTH CARE UTILIZATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; MATHEMATICAL MODEL; PRIORITY JOURNAL; TREATMENT OUTCOME; VACCINATION;

AIDS VACCINES; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MODELS, BIOLOGICAL; PUBLIC HEALTH; RISK ASSESSMENT; TREATMENT OUTCOME; VACCINATION; VIRAL LOAD;

EID: 34447305777     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3180959a94     Document Type: Article

References (106)

1. Balter M. AIDS now world's fourth biggest killer. Science. 1999;284:1101.
2. Klausner RD, Fauci AS, Corey L, et al. The need for a global HIV vaccine enterprise. Science. 2003;300:2036-2039.
3. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVAvaccine. Science. 2001;292:69-74.
4. Barouch DH, Santra S, Schmitz JE, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 2000;290:486-492.
5. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002;415:331-335.
6. Anderson R, Hanson M. Potential public health impact of imperfect HIV type 1 vaccines. J Infect Dis. 2005;191(Suppl 1):S85-S96.
7. Anderson RM, Garnett GP. Low-efficacy HIV vaccines: potential for community-based intervention programmes. Lancet. 1996;348:1010-1013.
8. Vermund SH. Rationale for the testing and use of a partially effective HIV vaccine. AIDS Res Hum Retroviruses. 1998;14(Suppl 3):S321-S323.
9. Clements-Mann ML. Lessons for AIDS vaccine development from non-AIDS vaccines. AIDS Res Hum Retroviruses. 1998;14(Suppl 3):S197-S203.
10. Heymann DL, Aylward RB. The polio eradication endgame. As polio eradication nears realization, such real-world vaccination strategies could hold lessons for the future in AIDS vaccine development. IAVI Rep. 2006;10:13-17.
11. Blower S, McLean A. AIDS - modeling epidemic control - reply. Science. 1995;267:1252-1253.
12. Blower S, Schwartz EJ, Mills J. Forecasting the future of HIVepidemics: the impact of antiretroviral therapies and imperfect vaccines. AIDS Rev. 2003;5:113-125.
13. Blower SM, Koelle K, Mills J. Health policy modeling: epidemic control, HIV vaccines and risky behavior. In: Brookmeyer KA, ed. Quantitative Evaluation of HIV Prevention Programs: New Haven, CT: Yale University Press; 2002:260-289.
14. Blower SM, McLean AR. Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco. Science. 1994; 265:1451-1454.
15. McLean AR, Blower SM. Imperfect vaccines and herd immunity to HIV. Proc R Soc Lond B Biol Sci. 1993;253:9-13.
16. McLean AR, Blower SM. Modelling HIV vaccination. Trends Microbiol. 1995;3:458-462.
17. Smith RJ, Blower SM. Could disease-modifying HIV vaccines cause population-level perversity? Lancet Infect Dis. 2004;4:636-639.
18. Anderson RM, Gupta S, May RM. Potential of community-wide chemotherapy or immunotherapy to control the spread of HIV-1. Nature. 1991;350:356-359.
19. Davenport MP, Ribeiro RM, Chao DL, et al. Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus. J Virol. 2004;78:11340-11351.
20. van Ballegooijen M, Bogaards JA, Weverling GJ, et al. AIDS vaccines that allow HIV-1 to infect and escape immunologic control: a mathematic analysis of mass vaccination. J Acquir Immune Defic Syndr. 2003;34:214-220.
21. Elbasha EH, Gumel AB. Theoretical assessment of public health impact of imperfect prophylactic HIV-1 vaccines with therapeutic benefits. Bull Math Biol. 2006;68:577-614.
22. Gumel AB, McCluskey CC, van den Driessche P. Mathematical study of a staged-progression HIV model with imperfect vaccine. Bull Math Biol. 2006;68:2105-2128.
23. Massad E, Coutinho FAB, Burattini MN, et al. Modeling the impact of imperfect HIV vaccines on the incidence of the infection. Math Comput Model. 2001;34:345-351.
24. Bogaards JA, van Ballegooijen WM, Jan Weverling G, et al. Is population-level perversity a likely outcome of mass vaccination against HIV? Lancet Infect Dis. 2005;5:254.
25. Blower SM, Smith RJ. Is population-level perversity a likely outcome of mass vaccination against HIV? Authors' reply. Lancet Infect Dis. 2005;5:255-256.
26. Halloran ME, Struchiner CJ, Longini IM Jr. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol. 1997;146:789-803.
27. Gilbert PB, DeGruttola VG, Hudgens MG, et al. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. J Infect Dis. 2003;188:179-193.
28. Datta S, Halloran ME, Longini IM Jr. Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy. Stat Med. 1998;17:185-200.
29. Longini IM Jr, Datta S, Halloran ME. Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:440-447.
30. Longini IM Jr, Hudgens MG, Halloran ME, et al. A Markov model for measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines. Stat Med. 1999;18:53-68.
31. Douek DC, Kwong PD, Nabel GJ. The rational design of an AIDS vaccine. Cell. 2006;124:677-681.
32. Kamb ML, Fishbein M, Douglas JM Jr, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA. 1998;280:1161-1167.
33. Kilian AH, Gregson S, Ndyanabangi B, et al. Reductions in risk behaviour provide the most consistent explanation for declining HIV-1 prevalence in Uganda. AIDS. 1999;13:391-398.
34. The NIMH Multisite HIV Prevention Trial. Reducing HIV sexual risk behavior. The National Institute of Mental Health (NIMH) Multisite HIV Prevention Trial Group. Science. 1998;280:1889-1894.
35. Brown EL, Wald A, Hughes JP, et al. High risk of human immunodeficiency virus in men who have sex with men with herpes simplex virus type 2 in the EXPLORE study. Am J Epidemiol. 2006;164:733-741.
36. Imrie J, Stephenson JM, Cowan FM, et al. A cognitive behavioural intervention to reduce sexually transmitted infections among gay men: randomised trial. BMJ. 2001;322:1451-1456.
37. Koblin B, Chesney M, Coates T. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet. 2004;364:41-50.
38. Mbulaiteye SM, Mahe C, Whitworth JA, et al. Declining HIV-1 incidence and associated prevalence over 10 years in a rural population in south-west Uganda: a cohort study. Lancet. 2002;360:41-46.
39. Wawer MJ, Sewankambo NK, Serwadda D, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet. 1999;353:525-535.
40. Gray RH, Wawer MJ, Sewankambo NK, et al. Relative risks and population attributable fraction of incident HIV associated with symptoms of sexually transmitted diseases and treatable symptomatic sexually transmitted diseases in Rakai District, Uganda. Rakai Project Team. AIDS. 1999;13:2113-2123.
41. Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet. 1995;346:530-536.
42. Mehrotra D, Li X, Gilbert PB. A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trial. Biometrics. 2006;62:893-900.
43. Longini IM Jr, Halloran ME, Haber M. Estimation of vaccine efficacy from epidemics of acute infectious agents under vaccine-related heterogeneity. Math Biosci. 1993;117:271-281.
44. Longini IM Jr, Koopman JS, Haber M, et al. Statistical inference for infectious diseases. Risk-specific household and community transmission parameters. Am J Epidemiol. 1988;128:845-859.
45. Koopman JS, Little RJ. Assessing HIV vaccine effects. Am J Epidemiol. 1995;142:1113-1120.
46. Gilbert PB, Bosch RJ, Hudgens MG. Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials. Biometrics. 2003;59:531-541.
47. Hudgens MG, Hoering A, Self SG. On the analysis of viral load endpoints in HIV vaccine trials. Stat Med. 2003;22:2281-2298.
48. Longini IM Jr, Sagatelian K, Rida WN, et al. Optimal vaccine trial design when estimating vaccine efficacy for susceptibility and infectiousness from multiple populations. Stat Med. 1998;17:1121-1136.
49. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342:921-929.
50. Follmann D, Duerr A, Tabet S, et al. Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop. J Acquir Immune Defic Syndr. 2007;44:49-60.
51. Hirsch VM, Fuerst TR, Sutter G, et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol. 1996;70:3741-3752.
52. deWolf F, Spijkerman I, Schellekens PT, et al. AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS. 1997;11:1799-1806.
53. Geskus RB, Miedema FA, Goudsmit J, et al. Prediction of residual time to AIDS and death based on markers and cofactors. J Acquir Immune Defic Syndr. 2003;32:514-521.
54. Hubert JB, Burgard M, Dussaix E, et al. Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. The SEROCO Study Group. AIDS. 2000;14:123-131.
55. Rouzioux C, Hubert JB, Burgard M, et al. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis. 2005;192:46-55.
56. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995;122:573-579.
57. Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167-1170.
58. Pedersen C, Katzenstein T, Nielsen C, et al. Prognostic value of serum HIV-RNA levels at virologic steady state after seroconversion: relation to CD4 cell count and clinical course of primary infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:93-99.
59. Smith SM, Holland B, Russo C, et al. Retrospective analysis of viral load and SIVantibody responses in rhesus macaques infected with pathogenic SIV: predictive value for disease progression. AIDS Res Hum Retroviruses. 1999;15:1691-1701.
60. Watson A, Ranchalis J, Travis B, et al. Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J Virol. 1997;71:284-290.
61. Chesney MA, Chambers DB, Kahn JO. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:266-271.
62. van Griensvan F, Keawkungwal J, Tappero JW, et al. Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand. AIDS. 2004;18:295-301.
63. Lampinen TM, Chan K, Remis RS, et al. Sexual risk behaviour of Canadian participants in the first efficacy trial of a preventive HIV-1 vaccine. CMAJ. 2005;172:479-483.
64. Chen SY, Gibson S, Katz MH, et al. Continuing increases in sexual risk behavior and sexually transmitted diseases among men who have sex with men: San Francisco, Calif, 1999-2001, USA. Am J Public Health. 2002;92:1387-1388.
65. Dukers NH, Goudsmit J, deWit JB, et al. Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS. 2001;15:369-378.
66. Ekstrand ML, Stall RD, Paul JP, et al. Gay men report high rates of unprotected anal sex with partners of unknown or discordant HIV status. AIDS. 1999;13:1525-1533.
67. Katz MH, Schwarcz SK, Kellogg TA, et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health. 2002;92:388-394.
68. Scheer S, Chu PL, Klausner JD, et al. Effect of highly active antiretroviral therapy on diagnoses of sexually transmitted diseases in people with AIDS. Lancet. 2001;357:432-435.
69. Diamond C, Richardson JL, Milam J, et al. Use of and adherence to antiretroviral therapy is associated with decreased sexual risk behavior in HIV clinic patients. J Acquir Immune Defic Syndr. 2005;39:211-218.
70. Halloran ME, Longini IM Jr, Haber MJ, et al. Exposure efficacy and change in contact rates in evaluating prophylactic HIV vaccines in the field. Stat Med. 1994;13:357-377.
71. Schaper C, Fleming TR, Self SG, et al. Statistical issues in the design of HIV vaccine trials. Annu Rev Public Health. 1995;16:1-22.
72. Mortara L, Letourneur F, Gras-Masse H, et al. Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine. J Virol. 1998;72:1403-1410.
73. Kaul R, Rowland-Jones SL, Kimani J, et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J Clin Invest. 2001;107:341-349.
74. Anderson RM, Swinton J, Garnett GP. Potential impact of low efficacy HIV-1 vaccines in populations with high rates of infection. Proc Biol Sci. 1995;261:147-151.
75. Girard MP, Osmanov SK, Kieny MP. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine. 2006;24:4062-4081.
76. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford, UK: Oxford University Press; 1991.
77. Halloran ME, Watelet L, Struchiner CJ. Epidemiologic effects of vaccines with complex direct effects in an age-structured population. Math Biosci. 1994;121:193-225.
78. Arino J, McCluskey CC, Van den Driessche P. Global results for an epidemic model with vaccination that exhibits backward bifurcation. SIAM J Appl Math. 2003;64:260-276.
79. Dushoff J, Huang W, Castillo-Chavez C. Backwards bifurcations and catastrophe in simple models of fatal diseases. J Math Biol. 1998;36:227-248.
80. Kribs-Zaleta CM, Velasco-Hernandez JX. A simple vaccination model with multiple endemic states. Math Biosci. 2000;164:183-201.
81. Huang WZ, Cooke KL, Castillochavez C. Stability and bifurcation for a multiple-group model for the dynamics of HIV AIDS transmission. SIAM J Appl Math. 1992;52:835-854.
82. Arino J, Cooke KL, Van der Driessche P, et al. An epidemiology model that includes a leaky vaccine with a general waning function. Discrete and Continuous Dynamical Systems-Series B. 2004;4:479-495.
83. s82. Baggaley RF, Garnett GP, Ferguson NM. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med. 2006;3:e124.
84. Cohen MS, Hosseinipour M, Kashuba A, et al. Use of antiretroviral drugs to prevent sexual transmission of HIV. Curr Clin Top Infect Dis. 2002;22:214-251.
85. Marseille E, Hofmann PB, Kahn JG. HIV prevention before HAART in sub-Saharan Africa. Lancet. 2002;359:1851-1856.
86. Corbett EL, Steketee RW, ter Kuile FO, et al. HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet. 2002;359:2177-2187.
87. WHO/UNAIDS. Future access to HIV vaccines. Report from a WHO-UNAIDS consultation, Geneva, 2-3 October 2000. AIDS. 2001; 15:W27-W44.
88. Abu-Raddad LJ, Patnaik P, Kublin JG. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science. 2006;314:1603-1606.
89. Whitworth JA, Mahe C, Mbulaiteye SM, et al. HIV-1 epidemic trends in rural south-west Uganda over a 10-year period. Trop Med Int Health. 2002;7:1047-1052.
90. Asiimwe-Okiror G, Opio AA, Musinguzi J, et al. Change in sexual behaviour and decline in HIV infection among young pregnant women in urban Uganda. AIDS. 1997;11:1757-1763.
91. Kirungi WL, Musinguzi J, Madraa E, et al. Trends in antenatal HIV prevalence in urban Uganda associated with uptake of preventive sexual behaviour. Sex Transm Infect. 2006;82(Suppl 1):i36-i41.
92. Korenromp EL, Bakker R, de Vlas SJ, et al. HIV dynamics and behaviour change as determinants of the impact of sexually transmitted disease treatment on HIV transmission in the context of the Rakai trial. AIDS. 2002;16:2209-2218.
93. Hyman JM, Li J, Stanley EA. The differential infectivity and staged progression models for the transmission of HIV. Math Biosci. 1999;155:77-109.
94. McCluskey CC. A model of HIV/AIDS with staged progression and amelioration. Math Biosci. 2003;181:1-16.
95. Lansky A, Nakashima AK, Jones JL. Risk behaviors related to heterosexual transmission from HIV-infected persons. Supplement to HIV/AIDS Surveillance Study Group. Sex Transm Dis. 2000;27:483-489.
96. United Nations Program on HIV/AIDS, World Health Organization. AIDS epidemic update 2005. Available at: http://www.unaids.org/epi/ 2005/doc/report_pdf.asp. Accessed April 11, 2006.
97. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191:1403-1409.
98. Buve A, Carael M, Hayes RJ, et al. The multicentre study on factors determining the differential spread of HIV in four African cities: summary and conclusions. AIDS. 2001;15(Suppl 4):S127-S131.
99. Ferry B, Carael M, Buve A, et al. Comparison of key parameters of sexual behaviour in four African urban populations with different levels of HIV infection. AIDS. 2001;15(Suppl 4):S41-S50.
100. Lagarde E, Auvert B, Carael M, et al. Concurrent sexual partnerships and HIV prevalence in five urban communities of sub-Saharan Africa. AIDS. 2001;15:877-884.
101. Morison L, Weiss HA, Buve A, et al. Commercial sex and the spread of HIV in four cities in sub-Saharan Africa. AIDS. 2001;15(Suppl 4):S61-S69.
102. Abu-Raddad LJ, Ferguson NM. Characterizing the symmetric equilibrium of multi-strain host-pathogen systems in the presence of cross immunity. J Math Biol. 2005;50:531-558.
103. Diekmann O, Heesterbeek JAP. The basic reproduction ratio. Mathematical epidemiology of infectious diseases: model building, analysis, and interpretation. New York: John Wiley. 2000:73-98.
104. Heffernan JM, Smith RJ, Wahl LM. Perspectives on the basic reproductive ratio. J R Soc Interface. 2005;2:281-293.
105. Morgan D, Mahe C, Mayanja B, et al. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS. 2002;16:597-603.
106. Morgan D, Whitworth J. The natural history of HIV-1 infection in Africa. Nat Med. 2001;7:143-145.